| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,990,000 |
| Market
Cap: |
2.40(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.062 - $1.22 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1 |
1 |
1 |
1 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
20,788 |
20,788 |
353,058 |
410,690 |
| Total Sell Value |
$1,455 |
$1,455 |
$144,635 |
$250,581 |
| Total People Sold |
1 |
1 |
6 |
6 |
| Total Sell Transactions |
1 |
1 |
9 |
14 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orwin John A |
PRESIDENT & CEO |
• • – |
2024-04-11 |
4 |
B |
$0.01 |
$0 |
D/D |
1 |
1 |
0.01 |
1% |
|
| Serafini Tito |
|
– • – |
2024-04-01 |
4 |
S |
$0.07 |
$1,455 |
D/D |
(20,788) |
43,636 |
|
-7% |
|
| Baker Bros. Advisors (gp) Llc |
Former 10% Owner |
– – – |
2023-10-19 |
4 |
S |
$0.40 |
$110,582 |
I/I |
(274,739) |
2,971,128 |
|
29% |
|
| Ruiz Roger Richard |
VP of FinanceOfficer |
• – – |
2023-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
34,980 |
|
-31% |
|
| Orwin John A |
PRESIDENT & CEO |
• • – |
2023-09-01 |
4 |
S |
$0.37 |
$8,597 |
D/D |
(22,951) |
77,541 |
|
37% |
|
| Serafini Tito |
|
– • – |
2023-09-01 |
4 |
S |
$0.37 |
$3,144 |
D/D |
(8,393) |
64,424 |
|
37% |
|
| Courtney Phillips |
GENERAL COUNSEL & SECRETARY |
• – – |
2023-09-01 |
4 |
S |
$0.37 |
$2,645 |
D/D |
(7,061) |
50,431 |
|
37% |
|
| Courtney Phillips |
General Counsel & Secretary |
• – – |
2023-08-02 |
4 |
S |
$0.95 |
$3,881 |
D/D |
(4,076) |
57,492 |
|
74% |
|
| Gould Stephen E |
Chief Scientific Officer |
• – – |
2023-08-02 |
4 |
S |
$0.95 |
$3,881 |
D/D |
(4,076) |
28,424 |
|
74% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2023-08-02 |
4 |
S |
$0.95 |
$5,225 |
D/D |
(5,487) |
72,817 |
|
74% |
|
| Cross Herb |
Chief Financial Officer |
• – – |
2023-08-02 |
4 |
S |
$0.95 |
$5,225 |
D/D |
(5,487) |
72,817 |
|
74% |
|
| Courtney Phillips |
General Counsel & Secretary |
• – – |
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
61,568 |
|
- |
|
| Gould Stephen E |
Chief Scientific Officer |
• – – |
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
32,500 |
|
- |
|
| Cross Herb |
Chief Financial Officer |
• – – |
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
78,304 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
78,304 |
|
- |
|
| Orwin John A |
President & CEO |
• • – |
2022-09-02 |
4 |
S |
$1.78 |
$37,116 |
D/D |
(20,908) |
100,492 |
|
6% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2022-09-02 |
4 |
S |
$1.78 |
$13,573 |
D/D |
(7,646) |
34,554 |
|
6% |
|
| Courtney Phillips |
General Counsel & Secretary |
• – – |
2022-09-02 |
4 |
S |
$1.78 |
$11,418 |
D/D |
(6,432) |
29,068 |
|
6% |
|
| Cross Herb |
Chief Financial Officer |
• – – |
2022-09-02 |
4 |
S |
$1.78 |
$13,573 |
D/D |
(7,646) |
34,554 |
|
6% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2022-06-28 |
4 |
AS |
$2.02 |
$30,266 |
I/I |
(15,000) |
228,875 |
|
-21% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2022-03-04 |
4 |
AS |
$5.00 |
$150,000 |
I/I |
(30,000) |
243,875 |
|
-59% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2021-09-27 |
4 |
AS |
$6.58 |
$197,541 |
I/I |
(30,000) |
273,875 |
|
-71% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2021-09-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
50,000 |
50,000 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2021-09-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
50,000 |
303,875 |
|
- |
|
| Orwin John A |
President & CEO |
• • – |
2021-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
115,400 |
121,400 |
|
- |
|
132 Records found
|
|
Page 1 of 6 |
|
|
0.01 (6.43%) 
